 |
In 2003, the Hong Kong IPO market, then as now dominated by aspiring mainland corporates, started off with a bang before tailing off sharply as news of a deadly new pathogen emerged. Severe acute respiratory syndrome, or SARS, resulted in 774 deaths, with Hong Kong and Beijing hardest hit.
For a while, the city’s capital markets all but closed down. One after the other, mainland firms delayed their Hong Kong listing plans.
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
